SCHEMBL7541273

SCHEMBL7541273

CCOc1nc(C)cnc1C(=O)OC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 2/20 0.42
S1PR4 O95977 1/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 2/20 0.36
MAPT P10636 2/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
ALOX15 P16050 1/20 0.35
BRD4 O60885 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
KDM4E B2RXH2 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
RXFP1 Q9HBX9 1/20 0.35
GMNN O75496 1/20 0.35
LMNA P02545 1/20 0.35
CYP1A2 P05177 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
GABRA1 P14867 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7541370 0.89 ALDH1A1 (0.44) NPSR1KMT2AALDH1A1MAPTHTT
SCHEMBL7541379 0.85 NPSR1 (0.47) NPSR1S1PR4ALDH1A1MAPTSMN1; SMN2
SCHEMBL7547389 0.83 KDM4E (0.41) KMT2AALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL7542145 0.82 PARP10 (0.39) NPSR1ALDH1A1MAPTSMN1; SMN2KDM4E
SCHEMBL7543209 0.81 ALDH1A1 (0.43) NPSR1ALDH1A1MAPTHTTL3MBTL1
SCHEMBL7547883 0.81 DGAT1 (0.34) MAPTHTTL3MBTL1KDM4ENPC1
SCHEMBL5767143 0.79 NPSR1 (0.58) NPSR1S1PR4KMT2AALDH1A1SMN1; SMN2
SCHEMBL7542788 0.76 SLC13A5 (0.35) ALDH1A1MAPTSMN1; SMN2KDM4ENPC1
SCHEMBL24992979 0.75 NPC1 (0.47) ALDH1A1SMN1; SMN2L3MBTL1KDM4ENPC1
SCHEMBL5767151 0.75 NPSR1 (0.47) NPSR1S1PR4KMT2AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0889038-B1 Process for the preparation of alkoxy-or aryloxypyrazine derivatives LONZA AG (CH) 2002-05-29 EP claimed
US-20010012894-A1 Process for preparing alkoxypyrazine derivatives FUCHS RUDOLF (CH) 2001-08-09 US claimed
US-6066736-A Process for preparing alkoxypyrazine derivatives LONZA AG (CH) 2000-05-23 US claimed
US-6291674-B2 REACTING GLYOXAL DERIVATIVE AND AMINOIMIDATE DERIVATIVE TO FORM 3-ALKOXY/ARYLOXY-5-(ALKYL/ARYL)PYRAZINE-2-CARBOXAMIDE; REACTING WITH ALKALI METAL HYPOHALITE TO FORM 3-ALKOXY/ARYLOXY-5-(ALKYL/ARYL)PYRAZINE-2-AMINE LONZA AG (CH) 2001-09-18 US disclosed
US-20010012894-A1 Process for preparing alkoxypyrazine derivatives FUCHS RUDOLF (CH) 2001-08-09 US disclosed
US-6235905-B1 REACTING A GLYOXAL DERIVATIVE WITH A AMINOACETIMIDATE LONZA AG (CH) 2001-05-22 US disclosed
US-6066736-A Process for preparing alkoxypyrazine derivatives LONZA AG (CH) 2000-05-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010012894-A1 Process for preparing alkoxypyrazine derivatives CYP3A5, GMDS, CYP3A43 NPSR1 2997/4885S1PR4 3684/4885KMT2A 3024/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.